此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

针对急性白血病患者的情绪和以症状为中心的参与试验 (EASE)

2026年11月10日 更新者:Canadian Cancer Trials Group

情绪和以症状为中心的参与 (EASE):一项针对急性白血病患者的干预措施的多站点随机对照试验

The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early palliative care for symptom control, reduces psychological distress and physical symptom burden in individuals newly diagnosed with acute leukemia. To do this, half of the participants in this study will receive the usual care offered to patients with acute leukemia and half of the participants will receive usual care plus the EASE intervention.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

The standard or usual care treatment for patients with newly diagnosed acute leukemia involves admission to hospital for treatment (e.g. induction chemotherapy). Additional support services may be delivered if requested or if a doctor thinks it is necessary.

Little research has been done looking at the psychological and physical consequences of being diagnosed with and treated for acute leukemia, but our research team has found that a significant number of these individuals experience symptoms of traumatic stress and severe physical symptoms. Even less research has been done looking at ways to help alleviate this psychological and physical distress. Emotion and Symptom-focused Engagement (EASE) is an integrated psychosocial and early palliative care (symptom control) intervention designed to reduce psychological distress and physical symptom burden in patients newly diagnosed with acute leukemia. The EASE intervention provides i) tailored supportive psychotherapy (called EASE-psy) during the initial weeks of treatment to reduce symptoms of traumatic stress, and ii) symptom screening during the initial inpatient treatment period with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms (called EASE-phys).

A phase II trial of EASE in patients with newly diagnosed acute leukemia demonstrated feasibility and preliminary evidence that it reduces psychological distress and physical symptom severity compared to usual care. This new trial is a definitive phase III, multi-site randomized controlled trial to test the effectiveness of EASE at reducing psychological distress and physical burden.

研究类型

介入性

注册 (估计的)

196

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • New Brunswick
      • Saint John、New Brunswick、加拿大、E2L 4L2
        • 招聘中
        • Regional Health Authority B, Zone 2
        • 接触:
          • Alfonso Rivera Duarte
          • 电话号码:506 648-7109
    • Ontario
      • Hamilton、Ontario、加拿大、L8V 5C2
        • 招聘中
        • Juravinski Cancer Centre at Hamilton Health Sciences
        • 接触:
          • Alejandro Garcia-Horton
      • Kingston、Ontario、加拿大、K7L 2V7
        • 招聘中
        • Kingston Health Sciences Centre
        • 接触:
          • Annette Hay
          • 电话号码:77094 613 533-6430
      • Ottawa、Ontario、加拿大、K1H 8L6
        • 招聘中
        • Ottawa Hospital Research Institute
        • 接触:
          • Pierre Villeneuve
          • 电话号码:613
      • Toronto、Ontario、加拿大、M5G 2M9
        • 招聘中
        • University Health Network
        • 接触:
          • Gary Rodin
          • 电话号码:416 946-4504
      • Toronto、Ontario、加拿大、M4N 3M5
        • 招聘中
        • Odette Cancer Centre
        • 接触:
          • Lee Mozessohn
          • 电话号码:5847 416 480-5000

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
  • Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
  • Age ≥ 18 years.
  • Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
  • Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.

Exclusion Criteria:

  • Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
  • Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
  • Receiving on-site (in hospital) palliative care services at the time of recruitment.
  • A diagnosis of acute promyelocytic leukemia.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:其他:日常护理

The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial

实验性的:Behavioral: Usual Care + EASE Intervention-psy

EASE Intervention = EASE-psy + EASE-phys

All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT).

-EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Assess the effect of the EASE intervention compared to usual care to reduce traumatic stress symptoms using the Stanford Acute Stress Reaction questionnaire (SASRQ)
大体时间:4 weeks

This 30-item measure assesses severity of traumatic stress symptoms over the past four weeks; it has been updated to be Diagnostic and Statistical Manual of Mental Disorders (DSM-5)-concordant [American Psychiatric Association 2013] for acute stress disorder (ASD). Mean severity of traumatic stress symptoms at 4 weeks will be the first primary outcome

4 weeks

次要结果测量

结果测量
措施说明
大体时间
使用 SASRQ 评估 EASE 干预与常规护理相比减少创伤应激症状的效果
大体时间:8周、12周和26周
8周、12周和26周
使用 MSAS 评估 EASE 干预对常规护理的影响,以减轻身体症状的严重程度
大体时间:8周、12周和26周
8周、12周和26周
使用 SASRQ 根据 DSM-5 标准评估 EASE 干预与常规护理相比对符合 ASD 诊断标准和阈值 ASD 的参与者数量的影响
大体时间:4、8、12 和 26 周
4、8、12 和 26 周
与常规护理相比,评估 EASE 干预对癌症身体症状数量的影响以及通过 (MSAS) 测量的相关症状相关痛苦
大体时间:4、8、12 和 26 周
4、8、12 和 26 周
使用 16 项 FAMCAR-P16 评估 EASE 干预与常规护理相比对患者护理满意度的影响
大体时间:4、8、12 和 26 周
4、8、12 和 26 周
10) EQ-5D-5L 将用于测量一般健康状况,以便在比较 EASE 干预的收益和成本的经济评估中用于计算质量调整生命年 (QALY)
大体时间:4、8、12、26 和 52 周
4、8、12、26 和 52 周
比较治疗组之间的无进展生存期
大体时间:1年
1年
Assess the effect of the EASE intervention compared to usual care to reduce physical symptom severity using the Memorial Symptom Assessment Scale (MSAS)
大体时间:4 weeks

This reliable and valid instrument assesses symptom prevalence, severity and distress associated with 26 common physical and 6 psychological symptoms of cancer. Mean physical symptom severity at 4 weeks will be the second primary outcome

4 weeks
Assess the effect of the EASE intervention compared to usual care on Quality of Life using The Functional Assessment of chronic Illness Therapy-Spiritual Well-being Scale
大体时间:4, 8, 12, 26 and 52 weeks

Individual subscales of the FACIT-Sp provide scores for physical, social/family, emotional, functional spiritual well-being

4, 8, 12, 26 and 52 weeks
Assess the effect of the EASE intervention compared to usual care on depressive symptoms using The Patient Health Questionnaire-9 (PHQ-9)
大体时间:4, 8 ,12 and 26 weeks

This valid 9-item measure of depression has been widely used with patients with advanced cancer. Two additional items assessing intent to cause self-harm and interference with daily activities were included in the measure to ensure patients' safety but are not considered for data analysis.

4, 8 ,12 and 26 weeks
Assess the effect of the EASE intervention compared to usual care on pain using the modified Brief Pain Inventory-Sort Form (BPI)
大体时间:4, 8 12 and 26 weeks

The BPI is a widely used measure to rapidly assess the severity of pain and its impact on functioning and will be assessed as part of the secondary outcomes

4, 8 12 and 26 weeks
The modified brief Experiences in Close Relationships Scale (ECR-M16) is an instrument to measure attachment security or the ability to rely on close others for support when distressed.
大体时间:Baseline

It provides subscale scores assessing attachment anxiety (i.e. fear of abandonment) and attachment avoidance (i.e. defensive independence). The ECR-M16 will only be administered at baseline in both arms of the study.

Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 学习椅:Gary Rodin、Princess Margaret Hospital, Canada
  • 学习椅:Camilla Zimmerman、Princess Margaret Hospital, Canada

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年1月6日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2019年12月20日

首先提交符合 QC 标准的

2020年1月8日

首次发布 (实际的)

2020年1月13日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • SC26

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.